Saint Luke's Hospital of Kansas City is a tertiary care hospital is located at 4401 Wornall Road in Kansas City, Missouri. It is part of the Saint Luke's Health System.

During the past decade, Saint Luke's Hospital of Kansas City conducted 164 clinical trials. In the 10-year time frame, 164 clinical trials started and 170 clinical trials were completed, i.e. on average, 103.7% percent of trials that started reached the finish line to date. In the past 5 years, 45 clinical trials started and 85 clinical trials were completed. i.e. 188.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Saint Luke's Hospital of Kansas City" #1 sponsor was "National Cancer Institute (NCI)" with 85 trials, followed by "SWOG Cancer Research Network" with 28 trials sponsored, "Abbott Medical Devices" with 23 trials sponsored, "Alliance for Clinical Trials in Oncology" with 22 trials sponsored and "Boston Scientific Corporation" with 22 trials sponsored. Other sponsors include 205 different institutions and companies that sponsored additional 126 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Saint Luke's Hospital of Kansas City" #1 collaborator was "National Cancer Institute (NCI)" with 76 trials as a collaborator, "NRG Oncology" with 18 trials as a collaborator, "Canadian Cancer Trials Group" with 7 trials as a collaborator, "Genentech, Inc." with 7 trials as a collaborator and "NCIC Clinical Trials Group" with 5 trials as a collaborator. Other collaborators include 149 different institutions and companies that were collaborators in the rest 117 trials.

According to Clinical.Site data, the most researched conditions in "Saint Luke's Hospital of Kansas City" are "Coronary Artery Disease" (19 trials), "Heart Failure" (17 trials), "Breast Cancer" (13 trials), "Stroke" (12 trials) and "Atrial Fibrillation" (10 trials). Many other conditions were trialed in "Saint Luke's Hospital of Kansas City" in a lesser frequency.

Most popular intervention types in "Saint Luke's Hospital of Kansas City" are "Drug" (218 trials), "Other" (139 trials), "Device" (104 trials), "Biological" (68 trials) and "Procedure" (46 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (74 trials), "Quality-of-Life Assessment" (41 trials), "Placebo" (38 trials), "Paclitaxel" (25 trials) and "Carboplatin" (22 trials). Other intervention names were less common.

The vast majority of trials in "Saint Luke's Hospital of Kansas City" are 332 trials for "All" genders, 53 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Saint Luke's Hospital of Kansas City". undefined are not yet recruiting, 48 are recruiting, 117 are Active, not recruiting, and 5 are Enrolling by invitation. In total, there were 160 completed trials in Saint Luke's Hospital of Kansas City, 1 suspended trials, and 40 terminated clinical trials to date.

Out of the total trials that were conducted in Saint Luke's Hospital of Kansas City, 10 "Phase 1" clinical trials were conducted, 108 "Phase 2" clinical trials and 152 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 82 trials that are defined as “Not Applicable".

Saint Luke's Hospital of Kansas City has several departments that took part in Clinical trials: "Saint Luke's Cancer Institute at Saint Luke's Hospital" - 109 trials, "Mid America Heart Institute" - 67 trials, "Kansas City Oncology and Hematology Group" - 18 trials, "Cardiovascular Consultants" - 10 trials, "St. Luke's Brain and Stroke Institute" - 5 trials